Key facts
- Biograil’s last known valuation is $31.5M (Dec 2025).
- It has raised $21.1M; the latest was Later Stage VC ($11.2M) in Dec 2025.
- Notable investors include High-Tech Gründerfonds, Kinled Holding, Verve Ventures, Evonik Venture Capital, Sanner Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Biograil
- ·The full record, as it builds
Funding rounds
No funding rounds for Biograil are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biograil
Developer of a medical device designed to replace the standard injection system of medicines. The company's device is based upon an injection molding technique and uses the body's peristaltic forces to facilitate the delivery of the biologic efficiently into the gastrointestinal wall, enabling patients to receive medicines painlessly.
- Sector
- Healthcare
- HQ
- Roskilde, Denmark
- Founded
- 2019
- Employees
- 28
- Website
- biograil.com/
- Ownership
- Privately Held (backing)
Biograil doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biograil shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biograil in its N-PORT filings yet. We sweep new filings monthly.